Rein Therapeutics Files 8-K
Ticker: RNTX · Form: 8-K · Filed: Oct 9, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceuticals
TL;DR
Rein Therapeutics filed an 8-K on 10/9/25, nothing major to see here.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on October 9, 2025, reporting other events and financial statements. The company, formerly known as Aileron Therapeutics, Inc., is based in Austin, Texas, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting other events and financial statements, with no immediate indication of significant risk.
Key Numbers
- 001-38130 — Commission File Number (Identifies the company's filing with the SEC.)
- 13-4196017 — I.R.S. Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- October 9, 2025 (date) — Date of report
- 12407 N. Mopac Expy., Suite 250, #390 Austin, Texas 78758 (address) — Principal executive offices
- 737-802-1989 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing itself does not detail the specific 'Other Events' beyond listing it as an item information category. Further details would require examining the full document content beyond the provided header information.
When did Rein Therapeutics, Inc. change its name from Aileron Therapeutics, Inc.?
The filing indicates the date of name change from Aileron Therapeutics, Inc. to Rein Therapeutics, Inc. was March 29, 2024.
What is the primary business of Rein Therapeutics, Inc.?
Rein Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where are Rein Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Rein Therapeutics, Inc. are located at 12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758.
What is the filing date of this 8-K report?
The report was filed on October 9, 2025, and the earliest event reported is also dated October 9, 2025.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-10-09 07:45:46
Filing Documents
- d11439d8k.htm (8-K) — 24KB
- d11439dex991.htm (EX-99.1) — 10KB
- 0001193125-25-235152.txt ( ) — 153KB
- rntx-20251009.xsd (EX-101.SCH) — 3KB
- rntx-20251009_lab.xml (EX-101.LAB) — 18KB
- rntx-20251009_pre.xml (EX-101.PRE) — 11KB
- d11439d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits The following exhibits are filed with this report: Exhibit 99.1 The Company's press release dated October 9, 2025 Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REIN THERAPEUTICS, INC. Dated: October 9, 2025 /s/ Brian Windsor Brian Windsor, Ph.D., Chief Executive Officer